39995-50-1

Usage

Uses

Used in Ophthalmology:
2,2,2-TRIFLUORO-N-[(R)-ALPHA-METHYLBENZYL]ACETAMIDE is used as an antiviral medication for the treatment of herpes simplex infections of the eye. It is applied to reduce the symptoms and duration of the infection, providing relief to patients suffering from ocular herpes.
Used in Oncology Research:
2,2,2-TRIFLUORO-N-[(R)-ALPHA-METHYLBENZYL]ACETAMIDE is being studied for its potential use in the treatment of certain types of cancer. Its antiviral properties are being investigated for their possible application in cancer therapy, suggesting that 2,2,2-TRIFLUORO-N-[(R)-ALPHA-METHYLBENZYL]ACETAMIDE may have broader implications for human health beyond its established use in ophthalmology.

InChI:InChI=1/C10H10F3NO/c1-7(8-5-3-2-4-6-8)14-9(15)10(11,12)13/h2-7H,1H3,(H,14,15)/t7-/m1/s1

Upstream product

• 2627-86-3 (S)-1-phenyl-ethylamine 
• 407-25-0 trifluoroacetic anhydride 
• 354-38-1 2,2,2-trifluoroacetamide 
• 62288-65-7 2,2,2-trifluoro-N-(1-phenylvinyl)acetamide 
• 3886-69-9 (R)-1-phenyl-ethyl-amine 
• 383-63-1 ethyl trifluoroacetate, 
• 183266-61-7 1-(trifluoroacetyl)benzotriazole 
• 76-05-1 trifluoroacetic acid 
• 23943-56-8 P,P-diphenyl-N-[(1R)-1-phenylethyl]phosphinic amide 
• 431-47-0 trifluoroacetic acid-methyl ester 
• 929632-72-4 C₁₇H₁₆F₃NO₃S 
• 98-86-2 acetophenone 
• 613-91-2 acetophenone oxime 

Downstream Products

• 130632-94-9 (-)-2,2,2-trifluoro-N-(α-methylbenzyl)acetimidoyl chloride 
• 203186-18-9 (S)-2,2,2-trifluoro-N-(1-(4-iodophenyl)ethyl)ethanamide 
• 182141-70-4 N-[(1S)-1-(4-bromophenyl)ethyl]-2,2,2-trifluoroacetamide 
• 447459-97-4 2,2,2-trifluoro-N-{1-[4-(4-methoxy-benzenesulfonyl)-phenyl]-ethyl}-acetamide 
• 27298-97-1 (S)-1-(4-bromophenyl)ethylamine 
• 56639-48-6 4-iodo-α(S)-methyl-benzylamine 
• 203186-20-3 (R)-2-[(S)-1-(4-Iodo-phenyl)-ethylamino]-propionic acid ethyl ester 
• 441772-08-3 (R)-1-[(S)-1-(4-Bromo-phenyl)-ethyl]-2-methyl-piperazine 
• 203186-25-8 (R)-1-[(S)-1-(4-Iodo-phenyl)-ethyl]-2-methyl-piperazine 
• 441772-07-2 (R)-1-[(S)-1-(4-Bromo-phenyl)-ethyl]-6-methyl-piperazine-2,5-dione 
• 203186-23-6 (R)-1-[(S)-1-(4-Iodo-phenyl)-ethyl]-6-methyl-piperazine-2,5-dione 
• 203186-21-4 (R)-2-{(2-Chloro-acetyl)-[(S)-1-(4-iodo-phenyl)-ethyl]-amino}-propionic acid ethyl ester 
• 441772-11-8 N-{1-[4-(benzo[1,3]dioxole-5-sulfonyl)-phenyl]-ethyl}-2,2,2-trifluoro-acetamide 
• 203186-29-2 1-tert-butoxycarbonyl-4-{4-[1(S)-(4-bromophenyl)-ethyl]-3(R)-methylpiperazin-1-yl}-piperidine 

Relevant academic research and scientific papers

Tuning the Circular Dichroism and Circular Polarized Luminescence Intensities of Chiral 2D Hybrid Organic–Inorganic Perovskites through Halogenation of the Organic Ions

Through the incorporation of various halogen-substituted chiral organic cations, the effects of chiral molecules on the chiroptical properties of hybrid organic–inorganic perovskites (HOIPs) are investigated. Among them, the HOIP having a Cl-substituted chiral cation exhibits the highest circular dichroism (CD) and circular polarized luminescence (CPL) intensities, indicating the existence of the largest rotatory strength, whereas the F-substituted HIOP shows the weakest intensities. The observed modulation can be correlated to the varied magnetic transition dipole of HOIPs, which is sensitive to the d-spacing between inorganic layers and the halogen–halogen interaction between organic cations and the inorganic sheets. These counteracting effects meet the optimal CD and CPL intensity with chlorine substitution, rendering the rotatory strength of HOIPs arranged in the order of (ClMBA)2PbI4>(BrMBA)2PbI4>(IMBA)2PbI4>(MBA)2PbI4>(FMBA)2PbI4.

PYRAZOLO-TRIAZINE AND/OR PYRAZOLO-PYRIMIDINE DERIVATIVES AS SELECTIVE INHIBITOR OF CYCLIN DEPENDENT KINASE

The present invention relates to pyrazolo[1,5-a][1,3,5]triazine and pyrazolo[l,5-a]pyrimidine derivatives and/or pharmaceutically acceptable salts thereof, the use of these derivatives as pharmaceutically active agents, especially for the prophylaxis and/or treatment of cell proliferative diseases, inflammatory diseases, immunological diseases, cardiovascular diseases and infectious diseases. Furthermore, the present invention is directed towards pharmaceutical compositions containing at least one of the pyrazolo[1,5-a][1,3,5]triazine and pyrazolo[1,5-a]pyrimidine derivatives and/or pharmaceutically acceptable salts thereof.

Diastereoselective synthesis of polyfluoroalkylated α-aminophosphonic acid derivatives

The asymmetric synthesis of biorelevant aminophosphonates and aminophosphonic acids bearing trifluoromethyl, tetrafluoroethyl, perfluoropropyl or chlorodifluoromethyl group in the α-position to phosphonyl group is developed. Diastereoselective reduction o

meta-Selective C?H Borylation of Benzylamine-, Phenethylamine-, and Phenylpropylamine-Derived Amides Enabled by a Single Anionic Ligand

Selective functionalization at the meta position of arenes remains a significant challenge. In this work, we demonstrate that a single anionic bipyridine ligand bearing a remote sulfonate group enables selective iridium-catalyzed borylation of a range of common amine-containing aromatic molecules at the arene meta position. We propose that this selectivity is the result of a key hydrogen bonding interaction between the substrate and catalyst. The scope of this meta-selective borylation is demonstrated on amides derived from benzylamines, phenethylamines and phenylpropylamines; amine-containing building blocks of great utility in many applications.

Self-Disproportionation of Enantiomers (SDE) via achiral gravity-driven column chromatography of N-fluoroacyl-1-phenylethylamines

The study of the self-disproportionation of enantiomers (SDE) via gravity-driven achiral column chromatography of a series of N-fluoroacetylated amides derived from 1-phenylethylamine is described. The chromatographic experiments performed with N-fluoroacetylated amides confirmed, that the process of molecular association in solution leading to the SDE manifestation, is sensitive to the fluorine content and type of solvent used. Thus, the two opposite eluting profiles for the same compound were observed in two different eluents. Moreover, the amides bearing perfluoroalkyl groups showed opposite eluting order as compared to the established profile for fluorine-free N-acetyl-1-phenylethylamine.

Acetic acid as a catalyst for the N-acylation of amines using esters as the acyl source

We report a cheap and simple method for the acetylation of a variety of amines using catalytic acetic acid and either ethyl acetate or butyl acetate as the acyl source. Catalyst loadings as low as 10 mol% afforded acetamide products in excellent yields at temperatures ranging from 80-120 °C. The methodology can also be successfully applied for the synthesis of a broad range of other amides, including the formation of formamides at 20 °C.

Practical enantioselective hydrogenation of α-aryl- and α-carboxyamidoethylenes by rhodium(I)-{1,2-bis[(o-tert-butoxyphenyl) (phenyl)phosphino]ethane}

The rhodium(I)-{1,2-bis[(o-tert-butoxyphenyl)(phenyl)phosphino]ethane} [Rh(I)-(t-Bu-SMS-Phos)] catalyst system displayed prime efficiency in the hydrogenation of large series of aamidostyrenes and a-amidoacrylates. Up to >99.9% enantiomeric excesses coupl

Transamidation of primary amides with amines catalyzed by zirconocene dichloride

Zirconocene dichloride (Cp2ZrCl2) has been shown to be an effective catalyst for the transamidation of primary amides with amines in cyclohexane at 80°C in 5-24 hours. For favourable substrates, the reaction can be performed at temperatures as low as 30°C.

Transamidation of primary amides with amines catalyzed by zirconocene dichloride

Zirconocene dichloride (Cp2ZrCl2) has been shown to be an effective catalyst for the transamidation of primary amides with amines in cyclohexane at 80°C in 5-24 hours. For favourable substrates, the reaction can be performed at temperatures as low as 30°C.

Discovery of novel sphingosine kinase-1 inhibitors. Part 2

Building on our initial work, we have identified additional novel inhibitors of sphingosine kinase-1 (SK1). These new analogs address the shortcomings found in our previously reported compounds. Inhibitors 51 and 54 demonstrated oral bioavailability in a